Michael L. Jackson, PhD, MPH, focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Kaiser Permanente Washington Health Research Institute (KPWHRI) principal investigator for the United States Influenza Vaccine Effectiveness (US Flu VE) Network. Using information from five sites across the country, including Kaiser Permanente Washington, this network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies.
In addition, Dr. Jackson is using data collected by the US Flu VE Network to build a simulation model for the spread of influenza, with a specific focus on understanding when new strains of the influenza virus can out-compete existing strains. This work, funded by the National Institutes of Health, aims to improve our ability to correctly choose which strains of the influenza virus to include in seasonal influenza vaccines. He also uses simulation models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenzae type b (Hib) and Neisseria meningitidis.
Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration among nine U.S. managed care organizations and the Centers for Disease Control and Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the safety of childhood immunizations and develops methods for using managed care data for vaccine safety studies.
While studying for his PhD at the University of Washington, Dr. Jackson was a graduate research associate with KPWHRI from 2002 to 2007, and then a postdoctoral fellow at KPWHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib disease in the U.S. during the 2008–2009 shortage of Hib vaccines. He returned to KPWHRI as an assistant investigator in 2010. He is an affiliate associate professor at the University of Washington School of Public Health.
Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A, Reis M, Chung JR, Piedra PA, Avadhanula V, Nowalk MP, Zimmerman RK, Jackson ML, Jackson LA, Petrie JG, Ohmit SE, Monto AS, McLean HQ, Belongia EA, Fry AM, Flannery B. Influenza vaccine effectiveness against the 2009 pandemic A(H1N1) virus differed by vaccine type during 2013-14 in the United States. J Infect Dis. 2016 May 15;213(10):1546-56. doi: 10.1093/infdis/jiv577. Epub 2016 Jan 6. PubMed
Spencer S, Clippard J, Thompson M, Piedra PA, Jewell A, Avadhanula V, Mei M, Jackson ML, Meece J, Sundaram M, Belongia EA, Cross R, Johnson E, Bullotta A, Rinaldo C, Gaglani M, Murthy K, Clipper L, Berman L, Flannery B. Factors associated with real time RT-PCR cycle threshold values among medically attended influenza episodes. J Med Virol. 2016 Apr;88(4):719-23. doi: 10.1002/jmv.24373. Epub 2015 Sep 21. PubMed
Texier G, Farouh M, Pellegrin L, Jackson ML, Meynard JB, Deparis X, Chaudet H. Outbreak definition by change point analysis: a tool for public health decision? BMC Med Inform Decis Mak. 2016 Mar 12;16(1):33. doi: 10.1186/s12911-016-0271-x. PubMed
Thompson MG, Clippard J, Petrie JG, Jackson ML, McLean HQ, Gaglani M, Reis EC, Flannery B, Monto AS, Jackson L, Belongia EA, Murthy K, Zimmerman RK, Thaker S, Fry AM. Influenza vaccine effectiveness for fully and partially vaccinated children 6 months to 8 years old during 2011-2012 and 2012-2013: the importance of two priming doses. Pediatr Infect Dis J. 2016 Mar;35(3):299-308. doi: 10.1097/INF.0000000000001006. PubMed
Glanz JM, Newcomer SR, Jackson ML, Omer SB, Bednarczyk RA, Shoup JA, DeStefano F, Daley MF. White Paper on studying the safety of the childhood immunization schedule in the Vaccine Safety Datalink. Vaccine. 2016;34 Suppl 1:A1-A29. doi: 10.1016/j.vaccine.2015.10.082. PubMed
Chung JR, Flannery B, Thompson MG, Gaglani M, Jackson ML, Monto AS, Nowalk MP, Talbot HK, Treanor JJ, Belongia EA, Murthy K, Jackson LA, Petrie JG, Zimmerman RK, Griffin MR, McLean HQ, Fry AM. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics. 2016 Feb;137(2):e20153279. doi: 10.1542/peds.2015-3279. Epub 2016 Jan 5. PubMed
Kharbanda EO, Vazquez-Benitez G, Lipkind HS, Klein NP, Cheetham C, Naleway AL, Lee GM, Hambidge S, Jackson ML, Omer SB, McCarthy N, Nordin JD. Maternal Tdap vaccination: coverage and acute safety outcomes in the Vaccine Safety Datalink, 2007-2013. Vaccine. 2016 Jan 4. pii: S0264-410X(15)01843-5. doi: 10.1016/j.vaccine.2015.12.046. [Epub ahead of print].
Zimmerman RK, Balasubramani GK, Nowalk MP, Eng H, Urbanski L, Jackson ML, Jackson LA, McLean HQ, Belongia EA, Monto AS, Malosh RE, Gaglani M, Clipper L, Flannery B, Wisniewski SR. Classification and Regression Tree (CART) analysis to predict influenza in primary care patients. BMC Infect Dis. 2016 Sep 22;16(1):503. PubMed
Petrie JG, Cheng C, Malosh RE, VanWormer JJ, Flannery B, Zimmerman RK, Gaglani M, Jackson ML, King JP, Nowalk MP, Benoit J, Robertson A, Thaker SN, Monto AS, Ohmit SE. Illness severity and work productivity loss among working adults with medically-attended acute respiratory illnesses: US influenza vaccine effectiveness network 2012-2013. Clin Infect Dis.2015 Nov 12. pii: civ952. [Epub ahead of print]. PubMed
Sukumaran L, McCarthy NL, Kharbanda EO, Weintraub ES, Vazquez-Benitez G, McNeil MM, Li R, Klein NP, Hambidge SJ, Naleway AL, Lugg MM, Jackson ML, King JP, DeStefano F, Omer SB, Orenstein WA. Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy. Obstet Gynecol. 2015 Nov;126(5):1069-74. doi: 10.1097/AOG.0000000000001066. PubMed
Vaccines given in last 20 years could prevent 50 million deaths in 112 countries
Answers to 4 questions about COVID-19 and this season's flu, from KPWHRI's Michael Jackson, PhD, MPH.
In a JAMA Viewpoint, Dr. Mike Jackson plans ahead to meet the challenges of continuing to evaluate new vaccines.
Verywell Health, Jan. 13, 2021
KPWHRI’s Michael L. Jackson, PhD, MPH, talks about influenza vaccine research in the age of the pandemic.
WebMD, Sept. 2, 2020